[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"UroTrials Company (GmbH)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100580278",false,"NCT06835218","PROCARE - PROstate Cancer Real World Evidence Registry","PROstate CAncer Real World Evidence Registry: RECURRENT AND METASTATIC PROSTATE CANCER","PROCARE","Inclusion Criteria:\n\n* Adult prostate cancer patients (age ≥18 years).\n* Diagnosis at time of study inclusion Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof) Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line)\n* Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, … line).\n* For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient.\n* Patients, who are able and willing to sign the informed consent form\n\nExclusion Criteria:\n\n• Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician","MALE","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","The aim of this registry study with long-term follow-up is to record the course of therapy and disease in patients with recurrent and metastatic prostate cancer. The following patient groups are planned:\n\n* Patients with a recurrence of PSA after surgical removal or radiation of the prostate due to prostate cancer; so-called PSA recurrence (relapse) or biochemical recurrence.\n* Patients with a PSA recurrence who have received treatment by hormone deprivation therapy (so-called androgen deprivation) and in whom the PSA value has nevertheless risen again without spreading to other organs or parts of the body, so-called non-metastatic castration-resistant prostate cancer.\n* Patients with proven spread to other organs or parts of the body (= metastases, e.g. in the bone) without hormone deprivation therapy having been initiated, so-called metastatic hormone-sensitive prostate cancer.\n* Patients with prostate cancer and spread to other organs or parts of the body (= metastases) in whom the tumor disease has progressed despite hormone withdrawal treatment (e.g. as evidenced by an increase in PSA), so-called metastatic castration-refractory prostate cancer.\n\nThese four groups of patients are enrolled and observed independently of each other at different time periods.",[24,25,26,27,28],"Prostate Cancer","Biochemical Recurrence of Malignant Neoplasm of Prostate","Non-metastatic Castration-resistant Prostate Cancer","Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","Metastatic Castration-resistant Prostate Cancer",[30],"prostate, cancer, metastatic, systemic therapy","RECRUITING","2026-03-10",{"date":34,"type":35},"2026-03-12","ACTUAL",{"date":37,"type":35},"2024-01-29",{"date":39,"type":20},"2032-12-31",{"name":41,"class":42},"UroTrials Company (GmbH)","NETWORK",53,""]